Bluejay Diagnostics, Inc. Research and Development Expense
Bluejay Diagnostics, Inc. (BJDX) reported Research and Development Expense of $1.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Bluejay Diagnostics, Inc. research and development expense for the quarter ending 2026-06-30 was $1.44M, a 61.57% increase year-over-year.
- Bluejay Diagnostics, Inc. research and development expense for the quarter ending 2026-03-31 was $811.84K, a 3.45% increase year-over-year.
- Bluejay Diagnostics, Inc. research and development expense for the quarter ending 2025-12-31 was $586.14K, a 5.80% increase year-over-year.
- Bluejay Diagnostics, Inc. research and development expense for the quarter ending 2025-09-30 was $785.61K, a 42.41% increase year-over-year.
- Bluejay Diagnostics, Inc. research and development expense for fiscal 2025 was $3.05M, a 12.25% decline from fiscal 2024.
- Bluejay Diagnostics, Inc. research and development expense for fiscal 2024 was $3.47M, a 39.25% decline from fiscal 2023.
- Bluejay Diagnostics, Inc. research and development expense for fiscal 2023 was $5.71M, a 37.63% increase from fiscal 2022.
- Bluejay Diagnostics, Inc. research and development expense for fiscal 2022 was $4.15M, a 261.70% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.44M 10-Q · filed 2026-08-12 | $2.25M 10-Q · filed 2026-08-12 | $2.84M derived: sum of 3 quarters · filed 2026-08-12 | $3.62M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $811.84K 10-Q · filed 2026-05-07 | $1.40M derived: sum of 2 quarters · filed 2026-05-07 | $2.18M derived: sum of 3 quarters · filed 2026-05-07 | $3.07M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $586.14K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $1.37M derived: sum of 2 quarters · filed 2026-03-06 | $2.26M derived: sum of 3 quarters · filed 2026-08-12 | $3.05M 10-K · filed 2026-03-06 |
| 2025-09-30 | $785.61K 10-Q · filed 2025-11-07 | $1.68M derived: sum of 2 quarters · filed 2026-08-12 | $2.46M 10-Q · filed 2025-11-07 | $3.01M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $889.90K 10-Q · filed 2026-08-12 | $1.67M 10-Q · filed 2026-08-12 | $2.23M derived: sum of 3 quarters · filed 2026-08-12 | $2.78M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $784.80K 10-Q · filed 2026-05-07 | $1.34M derived: sum of 2 quarters · filed 2026-05-07 | $1.89M derived: sum of 3 quarters · filed 2026-05-07 | $2.92M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $554.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $1.11M derived: sum of 2 quarters · filed 2026-03-06 | $2.14M derived: sum of 3 quarters · filed 2026-03-06 | $3.47M 10-K · filed 2026-03-06 |
| 2024-09-30 | $551.65K 10-Q · filed 2025-11-07 | $1.58M derived: sum of 2 quarters · filed 2025-11-07 | $2.92M 10-Q · filed 2025-11-07 | $4.21M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $1.03M 10-Q · filed 2025-08-07 | $2.37M 10-Q · filed 2025-08-07 | $3.65M derived: sum of 3 quarters · filed 2025-08-07 | $5.05M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.33M 10-Q · filed 2025-05-13 | $2.62M derived: sum of 2 quarters · filed 2025-05-13 | $4.02M derived: sum of 3 quarters · filed 2025-05-13 | $5.69M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.68M derived: sum of 2 quarters · filed 2025-03-31 | $4.36M derived: sum of 3 quarters · filed 2025-03-31 | $5.71M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.40M 10-Q · filed 2024-11-07 | $3.07M derived: sum of 2 quarters · filed 2024-11-07 | $4.43M 10-Q · filed 2024-11-07 | $5.75M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.68M 10-Q · filed 2024-08-14 | $3.03M 10-Q · filed 2024-08-14 | $4.35M derived: sum of 3 quarters · filed 2024-08-14 | $5.73M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $1.35M 10-Q · filed 2024-05-15 | $2.68M derived: sum of 2 quarters · filed 2024-05-15 | $4.06M derived: sum of 3 quarters · filed 2024-05-15 | $4.81M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $2.70M derived: sum of 2 quarters · filed 2024-03-28 | $3.46M derived: sum of 3 quarters · filed 2024-03-28 | $4.15M 10-K · filed 2024-03-28 |
| 2022-09-30 | $1.38M 10-Q · filed 2023-11-09 | $2.14M derived: sum of 2 quarters · filed 2023-11-09 | $2.83M 10-Q · filed 2023-11-09 | $3.29M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $756.28K 10-Q · filed 2023-08-14 | $1.45M 10-Q · filed 2023-08-14 | $1.91M derived: sum of 3 quarters · filed 2023-08-14 | $2.35M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $694.76K 10-Q · filed 2023-05-11 | $1.15M derived: sum of 2 quarters · filed 2023-05-11 | $1.59M derived: sum of 3 quarters · filed 2023-05-11 | $1.82M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $455.25K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $897.78K derived: sum of 2 quarters · filed 2023-03-20 | $1.12M derived: sum of 3 quarters · filed 2023-03-20 | $1.15M 10-K · filed 2023-03-20 |
| 2021-09-30 | $442.53K 10-Q · filed 2022-11-09 | $668.52K derived: sum of 2 quarters · filed 2022-11-09 | $692.70K 10-Q · filed 2022-11-09 | $1.11M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $225.99K 10-Q · filed 2022-08-10 | $250.18K 10-Q · filed 2022-08-10 | $669.24K derived: sum of 3 quarters · filed 2022-08-10 | $671.96K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $24.18K 10-Q · filed 2022-05-09 | $443.24K derived: sum of 2 quarters · filed 2022-05-09 | $445.97K derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $419.06K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $421.78K derived: sum of 2 quarters · filed 2022-03-10 | $527.25K 10-K · filed 2022-03-10 | |
| 2020-09-30 | $2.72K 10-Q · filed 2021-12-16 | $108.19K 10-Q · filed 2021-12-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |